Status:
UNKNOWN
Influence of Preprandial Metformin Administration on Carbohydrate Absorption
Lead Sponsor:
University Hospital, Lille
Conditions:
Impaired Glucose Tolerance
Type2 Diabetes
Eligibility:
FEMALE
18-60 years
Phase:
NA
Brief Summary
Type 2 diabetes is spreading worldwide as well as obesity. Metformin is the most prescribed antidiabetic medication. One suggested mechanism of action is by decreasing carbohydrate absorption. It is ...
Eligibility Criteria
Inclusion
- Obesity (BMI ≥30 kg/m2)
- Dysglycemia (HbA1c≥ 6,0 %)
- No anti diabetic medication
Exclusion
- No obesity (BMI \< 30 kg/m2)
- No dysglycemia (HbA1c \<6,0%)
- Treatment that might interfere with carbohydrate absorption (anti diabetic medication, antibiotics, probiotics, steroids)
- Anemia (Hb \<12 g/dL)
- Organ failure
- Inflammatory Bowel Disease
Key Trial Info
Start Date :
December 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04018105
Start Date
December 1 2022
End Date
December 1 2024
Last Update
August 19 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.